Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
1.00
Ask:
1.10
Spread: 0.10 (10.00%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

AGM Statement

24 Aug 2011 07:00

RNS Number : 9007M
Provexis PLC
24 August 2011
 



24 August 2011

Provexis plc

 

AGM Statement

 

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food, sports nutrition and medical food technologies, will hold its Annual General Meeting in Reading later today.

 

At the meeting Dawson Buck, the non-executive Chairman of the Company, will give the following update on developments:

 

 "The Company has made major progress over the past 18 months, specifically with the commercialisation of its lead technology Fruitflow and the recent acquisition of Science in Sport ("SiS").

 

Following the announcement of the long-term Alliance with DSM Nutritional Products ("DSM") in June 2010, DSM has made good progress in marketing Fruitflow to a broad range of global markets, attracting positive interest from a wide range of global, multinational and national brand owners in the functional food and dietary supplement sectors. The Alliance expects to see initial revenues from Fruitflow commence in the coming months and the Company looks forward to updating shareholders on this matter as and when appropriate.

 

The Company acquired SiS in June 2011. The Board are very pleased with the business and the opportunities it presents to the enlarged group. The Board strongly believe that through targeted investment SiS will achieve significant like for like revenue growth and margin improvement. As part of this investment the Directors expect to transfer production and distribution to a larger facility later in the year, in line with growth plans for the business. Defined marketing and selling strategies, together with new product launches and efficiencies from the supply chain, will underpin sales and profit growth in the business during 2012.

 

The SiS business presents the Company with a number of opportunities to bring new products to market to support 2012 growth; consequently the Board is currently reviewing the overall project pipeline for the Company in order to allocate resource and capital in the most effective way, in line with our growth targets.

 

We have a busy year ahead of us, with the main focus of the executive team being on delivering revenues from Fruitflow and growing the sales and profitability of the SiS business. We have sufficient resources to hand to deliver our targets and I look forward to a year of strong progress."

 

-ends-

 

For further information please contact:

 

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 833177

 

Bobbie Hilliam Tel: 020 7071 4317

Evolution Securities

 

Haggie Financial LLP: Tel: 020 7417 8989

Matthew Longbottom/Peter Rigby matthew.longbottom@haggie.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMEXLFLFVFLBBB
Date   Source Headline
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.